Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing clinical trials and pharmacology without systematic review or meta-analysis methodology.
PubMed 21668043 · doi:10.2165/11202240-000000000-00000
What was done
This narrative review summarizes the pharmacological properties, clinical efficacy, and tolerability of tesamorelin—a synthetic growth hormone-releasing hormone analogue—for HIV-associated central fat accumulation based on data from two 26-week clinical trials and their 52-week extension phases.
What was found
Subcutaneous tesamorelin reduced visceral adipose tissue (VAT), trunk fat, and waist circumference, and improved belly image distress without clinically significant changes in subcutaneous adipose tissue over 26 weeks. VAT reductions were maintained through 52 weeks in patients continuing therapy, but fat reaccumulated upon discontinuation. Treatment-emergent serious adverse events occurred in <4% of patients over 26 weeks, mostly consisting of injection-site reactions and growth hormone-associated effects such as arthralgia, headache, and peripheral oedema. Quantitative effect sizes and total sample sizes were not reported in the abstract.
Why it matters
Tesamorelin offers a targeted intervention for excess visceral fat in HIV-associated lipodystrophy. However, the loss of efficacy following discontinuation indicates that sustained benefits require ongoing administration.
Limits
The abstract describes a narrative review without systematic search criteria or meta-analytic pooling. Specific effect sizes, statistical comparisons, and total sample sizes are omitted, and data beyond 52 weeks were not available.
Cited by
- supports Tesamorelin stimulates growth hormone release and is uniquely effective at reducing visceral abdominal fat.